The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
This Clinical Practice Guideline (CPG) has been developed to assist physicians and other healthcare providers during the evaluation process of candidates for LT and to help them in the correct management of patients after LT.
This is the first update since then and is based on a comprehensive review of the recent literature, including data from randomised controlled trials, systematic reviews, meta-analyses, cohort, prospective and retrospective studies.
Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A joint guideline covering chapters on incidence and epidemiology, diagnosis and pathology, staging, management of local disease, management of locally advanced/metastatic disease, response evaluation and follow-up.
EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies recommended for patients with this type of cancer.
These guidelines focus on diagnosis and pathology/molecular biology, staging and risk assessment and management of biliary cancer including follow-up and long-term implications.